​

Catalyst Pharmaceuticals (CPRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CPRX Stock Forecast

Catalyst Pharmaceuticals (CPRX) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $24.10, with a high of $35.00 and a low of $15.50. This represents a 12.83% increase from the last price of $21.36.

$15 $19 $23 $27 $31 $35 High: $35 Avg: $24.1 Low: $15.5 Last Closed Price: $21.36

CPRX Stock Rating

Catalyst Pharmaceuticals stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (93.75%), 1 Hold (6.25%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 1 15 Strong Sell Sell Hold Buy Strong Buy

CPRX Price Target Upside V Benchmarks

TypeNameUpside
StockCatalyst Pharmaceuticals12.83%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$31.67
Last Closing Price$21.36$21.36$21.36
Upside/Downside--48.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2516---7
Sep, 2516---7
Aug, 2516---7
Jul, 2516---7
Jun, 2517---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 03, 2025Robert W. Baird$32.00$22.3243.37%49.81%
Feb 04, 2025Joel BeattyRobert W. Baird$28.00$23.0921.26%31.09%
Jan 10, 2025Andrew FeinH.C. Wainwright$35.00$21.9259.67%63.86%
Dec 21, 2022Truist Financial$18.00$19.15-6.01%-15.73%
Dec 21, 2022H.C. Wainwright$24.00$18.6029.03%12.36%
Dec 19, 2022Joseph CatanzaroPiper Sandler$20.00$16.4121.88%-6.37%
Aug 24, 2022Scott HenryRoth Capital$15.50$14.913.96%-27.43%
Aug 11, 2022Truist Financial$17.00$13.4626.30%-20.41%
Aug 11, 2022H.C. Wainwright$18.00$13.1337.09%-15.73%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 28, 2025StephensOverweightOverweighthold
Jan 10, 2025OppenheimerOutperformOutperformhold
Jan 10, 2025H.C. WainwrightBuyBuyhold
Aug 12, 2024OppenheimerBuyBuyhold
Aug 12, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024CitigroupBuyBuyhold
Jun 03, 2024H.C. WainwrightUnderperformUnderperformhold
May 10, 2024H.C. WainwrightUnderperformUnderperformhold
May 10, 2024H.C. WainwrightBuyBuyhold
Mar 27, 2024CitigroupUnderperformUnderperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.72$0.38$0.80$0.67$1.38----
Avg Forecast$0.69$0.40$0.73$0.54$1.22$1.50$1.86$2.00$2.30
High Forecast$0.72$0.41$0.78$0.55$1.23$1.70$2.23$2.36$2.61
Low Forecast$0.67$0.39$0.72$0.53$1.19$1.28$1.50$1.64$2.14
Surprise %4.35%-5.00%9.59%24.07%13.11%----

Revenue Forecast

$100M $250M $400M $550M $700M $850M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$119.07M$140.83M$214.20M$398.20M$491.73M----
Avg Forecast$118.12M$140.71M$211.56M$393.55M$483.67M$563.14M$637.52M$694.57M$767.23M
High Forecast$121.62M$144.87M$221.22M$395.14M$485.77M$618.67M$637.53M$694.62M$846.60M
Low Forecast$115.67M$137.78M$207.53M$392.57M$481.37M$532.72M$637.52M$694.52M$725.90M
Surprise %0.80%0.09%1.25%1.18%1.67%----

Net Income Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$74.98M$39.48M$83.08M$71.41M$163.89M----
Avg Forecast$78.49M$45.27M$83.49M$61.04M$137.57M$186.59M$231.27M$249.64M$261.63M
High Forecast$81.51M$47.02M$88.45M$62.16M$139.95M$193.79M$253.67M$268.46M$296.82M
Low Forecast$76.37M$44.05M$81.42M$59.92M$135.19M$145.93M$170.63M$186.56M$243.31M
Surprise %-4.47%-12.79%-0.50%16.99%19.13%----

CPRX Forecast FAQ

Is Catalyst Pharmaceuticals stock a buy?

Catalyst Pharmaceuticals stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Catalyst Pharmaceuticals is a favorable investment for most analysts.

What is Catalyst Pharmaceuticals's price target?

Catalyst Pharmaceuticals's price target, set by 16 Wall Street analysts, averages $24.1 over the next 12 months. The price target range spans from $15.5 at the low end to $35 at the high end, suggesting a potential 12.83% change from the previous closing price of $21.36.

How does Catalyst Pharmaceuticals stock forecast compare to its benchmarks?

Catalyst Pharmaceuticals's stock forecast shows a 12.83% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Catalyst Pharmaceuticals over the past three months?

  • October 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Catalyst Pharmaceuticals’s EPS forecast?

Catalyst Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $1.5, marking a 8.70% increase from the reported $1.38 in 2024. Estimates for the following years are $1.86 in 2026, $2 in 2027, and $2.3 in 2028.

What is Catalyst Pharmaceuticals’s revenue forecast?

Catalyst Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $563.14M, reflecting a 14.52% increase from the reported $491.73M in 2024. The forecast for 2026 is $637.52M, followed by $694.57M for 2027, and $767.23M for 2028.

What is Catalyst Pharmaceuticals’s net income forecast?

Catalyst Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $186.59M, representing an 13.85% increase from the reported $163.89M in 2024. Projections indicate $231.27M in 2026, $249.64M in 2027, and $261.63M in 2028.